We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Amgen Inc. said that Food and Drug Administration has granted priority review of its panitumumab treatment for patients with metastatic colorectal cancer in an announcement Monday after the market closed, and also announced Tuesday that it will triple the number of its employees in Japan by 2010 to begin selling its new cancer drugs on its own.
A new once-monthly injectable treatment for alcoholism is available starting today, offering patients and physicians another medical option for alcohol addiction.
Supernus Pharmaceuticals, Inc. announces the signing of a definitive licensing agreement with United Therapeutics Corporation for the development of UT-15C, United Therapeutics' oral prostacyclin analog.
PhytoMedical Technologies, Inc., through its wholly owned subsidiary, today announced that it has entered into an exclusive license agreement with Iowa State University Research Foundation Inc. (ISURF) to develop, market and distribute novel synthesized compounds derived from type A-1 polyphenols, which have been linked to insulin sensitivity by lead researcher, Dr. Richard Anderson of the USDA's Agricultural Research Service.
Passport Health, an immunization and travel health center with national headquarters in Baltimore, reports that its participation in vaccine trials will expand this year with several new clinical trials in the pipeline.
The FDA has issued a warning letter to Wyeth Pharmaceuticals, citing a "false or misleading" consumer brochure for its ReFacto Antihemophilic Factor (Recombinant), used in patients with hemophilia A.